Dementia/Alzheimer Disease
RSSArticles
-
Targeting Fyn Kinase in Alzheimer’s Disease: Another Failed Clinical Trial
In this multicenter Phase IIa clinical trial in mild Alzheimer’s disease dementia, the tyrosine kinase Fyn inhibitor AZD0540 had no significant effects after 52 weeks of treatment.
-
Amyloid, Tau, Neurodegeneration Diagnostic Framework to Predict Memory Decline Before the Onset of Dementia
In a population-based longitudinal study of older individuals without dementia, the inclusion of imaging biomarkers for amyloid, tau, and neurodegeneration modestly improved the ability to predict memory decline compared to a model that only used clinical data and APOE genotype.
-
Statin Use Moderately Reduces Dementia Risk After Concussions in Older Individuals
In a large population study, concussion in older adults resulted in significantly higher risk for dementia that was modestly reduced among those taking a statin.
-
Does Hormone Therapy Increase the Risk of Alzheimer’s Disease?
A large Finnish case-control study suggests that postmenopausal hormone therapy results in a 9-17% increase in the risk of Alzheimer’s disease. However, the small effect size, and likely confounding of use effect, does not provide strong evidence for a causal relationship.
-
REM Behavior Disorder, Dementia, and Parkinson’s Disease
In this well-designed prospective cohort study of patients with REM behavior disorder, the investigators reported that 73.5% of patients developed a neurodegenerative disorder after a 12-year follow-up.
-
Cholecystokinin as a Biomarker Linking Metabolic Function to Alzheimer’s Disease
In a study cohort from the Alzheimer’s Disease Neuroimaging Initiative, cerebrospinal fluid levels of cholecystokinin were associated with better outcomes that may reflect compensatory protection as Alzheimer’s disease pathology progresses. However, because of significant study limitations, these findings need to be validated in additional studies.
-
Thinking Outside of the ‘Alpha-Synuclein Box’: A Critical Role of Tau in Lewy Body Disorders
Neocortical tau pathology was associated with worse antemortem cognition in this large study of Parkinson’s disease dementia and dementia with Lewy bodies. Regional brain variations correlated with specific cognitive domains.
-
Predicting the Risk of Mild Cognitive Impairment Using Imaging Biomarkers
In this population-based study, researchers used imaging biomarkers of amyloid and neuronal injury to estimate an absolute risk of mild cognitive impairment in the elderly.
-
Amyloid-ß Pathology Induced by Contaminated Cadaver-Derived Growth Hormone
Cadaveric pituitary-derived growth hormone that previously was known to transmit Creutzfeldt-Jakob disease (CJD) also contains ß-amyloid. Growth hormone vials from cases associated with amyloid plaques in CJD patients cause amyloid plaque formation and cerebral amyloid angiopathy when injected intracranially into mice.
-
Apolipoprotein E and CSF Levels in Men and Women With Alzheimer’s Disease
Apolipoprotein E epsilon 4 (APOE4) genotype, the stronger genetic risk factor for late-onset Alzheimer’s disease, negatively affects cerebrospinal levels of tau protein in a sex-dependent manner, whereby the effect of APOE4 is stronger in women than men.